stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Return on equity
Recursion Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 September 2026 was −48.7%, up 10.8 percentage points from fiscal 2025 (−59.5%). Over the past ten years it has ranged from −110.8% (fiscal 2021) to 52.6% (fiscal 2020); the current reading is higher than 36% of that period. That is in line with the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −59.5% | 2.35 |
| FY2024 | −61.9% | 7.23 |
| FY2023 | −69.1% | (22.56) |
| FY2022 | −46.6% | (46.56) |
| FY2022 | 0.00% | 110.79 |
| FY2021 | −110.8% | (110.79) |
| FY2021 | 0.00% | (52.64) |
| FY2020 | 52.6% | 52.64 |
| FY2020 | 0.00% | (49.80) |
| FY2019 | 49.8% | 0.00 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| MBX MBX Biosciences, Inc. compare | −33.2% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| RXRX Recursion Pharmaceuticals, Inc. | −48.7% |
| PHVS Pharvaris N.V. compare | −71.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement